BKR-013
Metabolic Disorder
Phase 1/2Active
Key Facts
About BioKier
BioKier is pioneering an oral therapeutic approach to mimic the metabolic resolution seen after gastric bypass surgery, primarily for type 2 diabetes. Its platform utilizes colon-targeted delivery of safe, nutrient-based compounds like L-glutamine to stimulate gut hormones (incretins) that regulate glucose and lipids. The company has completed multiple clinical studies, is funded by SBIR grants, and is advancing its lead programs BKR-017 and BKR-013 as medical foods and/or drugs.
View full company profile